ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Icad Inc

Icad Inc (ICAD)

1.54
-0.05
(-3.14%)
Closed April 20 4:00PM
1.57
0.03
(1.95%)
After Hours: 7:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.54
Bid
1.50
Ask
1.57
Volume
67,632
1.52 Day's Range 1.62
1.05 52 Week Range 3.97
Market Cap
Previous Close
1.59
Open
1.59
Last Trade
60
@
1.54
Last Trade Time
Financial Volume
$ 105,931
VWAP
1.5663
Average Volume (3m)
214,719
Shares Outstanding
26,352,733
Dividend Yield
-
PE Ratio
-8.54
Earnings Per Share (EPS)
-0.18
Revenue
17.32M
Net Profit
-4.85M

About Icad Inc

icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed... icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. Its products include powerlook tomo detection, powerlook density assessment, and vera look. The firm has also developed a technology namely Xoft Axxent electronic brachytherapy system used in the treatment of non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers. Show more

Sector
Surgical,med Instr,apparatus
Industry
Computer Peripheral Eq, Nec
Website
Headquarters
Wilmington, Delaware, USA
Founded
2006
Icad Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ICAD. The last closing price for Icad was $1.59. Over the last year, Icad shares have traded in a share price range of $ 1.05 to $ 3.97.

Icad currently has 26,352,733 shares outstanding. The market capitalization of Icad is $41.37 million. Icad has a price to earnings ratio (PE ratio) of -8.54.

ICAD Latest News

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in early breast cancer detectionNew...

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk...

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates...

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic...

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of...

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably...

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA...

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.17-9.941520467841.711.731.4751042461.60608917CS
4-0.06-3.751.61.991.461684761.66643086CS
120.053.355704697991.492.64991.252147191.68794924CS
26-0.27-14.91712707181.812.64991.241932181.61998899CS
520.117.692307692311.433.971.054909402.65458346CS
156-16.07-91.254968767717.61191.052763164.09693873CS
260-2.99-66.0044150114.5321.441.052464756.28672811CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

ICAD Discussion

View Posts
dletizia dletizia 2 months ago
And those looking for an up-and-coming growth name with tremendous potential in the AI space should consider iCAD (NASDAQ: ICAD). The firm uses AI to detect breast cancer more proficiently than mammographies, and it has formed alliances with GE Healthcare (NASDAQ:GEHC), Alphabet (NASDAQ:GOOG,GOOGL), and two of America’s largest owners of clinics that specialize in mammographies.

In my view, iCAD’s current market capitalization of $38 million far undervalues the firm.

On the date of publication, Larry Ramer held long positions in SMCI and ICAD. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.

5 AI Stocks to Buy Before They Skyrocket

?

3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies

America’s #1 Top Trader, Eric Fry, just released his latest AI recommendations with trillion-dollar market cap valuations. Learn their names & full backstories in his new report while they’re still considered a bargain. Enter your email below to get your free copy of “3 AI-Driven Stocks That Will Be the Next Trillion-Dollar Companies” and a complimentary subscription to Eric Fry’s Smart Money e-letter. Get your FREE report now!

Submit

SPONSORED HEADLINES

?

5 Artificial Intelligence Stocks to Buy Before They Skyrocket

?

The Top 7 Stocks for 2024

?

ChatGPT IPO Could Shock the World, Make This Move Before the Announcement

?

“America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out

MORE FROM INVESTORPLACE

?

MARKET ANALYSIS

Why Today’s Inflation-Driven Flush Comes at the Perfect Time

17h ago · By Luke Lango, InvestorPlace Senior Investment Analyst

?

MARKET ANALYSIS

The Quest for Value: Intel vs. India Stocks

18h ago · By Eric Fry, Editor, Fry's Investment Report

?

TODAY'S MARKET

Mizuho Just Raised Its Price Target on Nvidia (NVDA) Stock

18h ago · By Chris MacDonald, InvestorPlace Contributor

 

 

About InvestorPlace

 

Products

 

Contact Us

 

Help

 

Careers

 

Advertise With Us

 

Disclosures & Disclaimers

 

Privacy Policy

 

Terms of Use

 

Ad Choices

 

Do Not Sell My Personal Information

 

Cookie Preferences

 

DMCA Policy

Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Copyright © 2024 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.


👍️0
starman2 starman2 3 months ago
Looking good
👍️0
dletizia dletizia 5 months ago
Partnerships keep coming,will pay off soon
👍️0
tigerpac tigerpac 5 months ago
During the third quarter, the company generated net proceeds of approximately $1.8 million from the issuance of 958,248 shares of common stock in the aftermarket ATM offerings at a weighted average price of $2.26 per share.

Only one analyst on the call. Now a standalone product line. They are hiring a bunch of new sales reps to try and get back the maintenance business that wasn’t renewed by prior customers. They said they won’t need to raise additional cash but revenue gains are going to be slow over the next year with this really being a 2025 story.
👍️0
tigerpac tigerpac 6 months ago
Retracement to lows from summer and getting a bounce now. Good time to start a position imo.
👍️0
tigerpac tigerpac 6 months ago
With the sale of Xsoft , expect the company to lose about $1.7 quarterly sales going forward (about $6.8 million annually). However it was never a money maker for them . Someone else will do a better job with the technology.
👍️0
tigerpac tigerpac 6 months ago
The Company currently expects to report revenue for the three months ended September 30, 2023 of between $5.4 million and $5.6 million. In addition, the Company expects total operating expenses for such period of between $5.5 million and $5.7 million. These expected results are not final and it is possible they will change upon filing of Form 10-Q on or before November 14, 2023.
👍️0
tigerpac tigerpac 6 months ago
Until some of the insiders step up to the plate and purchase their stock (not counting option grants) this is a no go for me right now. Obviously $1.70 is too expensive for even them at this point.
👍️0
tigerpac tigerpac 7 months ago
Craig-Hallum Capital is raising money thru the share offering any time the share price rises above 2.

Unfortunately, at some point, IMO they will lower that price ten cents at a time.
👍️0
dletizia dletizia 7 months ago
Yeah I must have missed it
👍️0
dletizia dletizia 7 months ago
Was this news even release by icad?
👍️0
dletizia dletizia 7 months ago
https://www.prnewswire.com/news-releases/simonmed-imaging-implements-3rd-generation-icad-breast-ai-3-0--301867503.html
👍️0
dletizia dletizia 7 months ago
Artificial Intelligence Mammograms - SimonMed Website https://www.simonmed.com/artificial-intelligence-mammograms/
👍️0
dletizia dletizia 8 months ago
Your welcome,just have some patience with this one,its gonna make some people alot of money
👍️0
tigerpac tigerpac 8 months ago
Got it now. I was thinking most pennies traded on the OTC but your explanation makes more sense.

Thanks!
👍️0
dletizia dletizia 8 months ago
They call anything under 5 bucks penny stocks these days
👍️0
tigerpac tigerpac 8 months ago
I hope this is not a harbinger of things to come, calling ICAD a “penny stock” when it’s $2/share.

👍️0
dletizia dletizia 8 months ago
first quarter.

Best AI Penny Stocks to Buy Now

10. iCAD, Inc. (NASDAQ:ICAD)

Number of Hedge Fund Holders: 7

iCAD, Inc. (NASDAQ:ICAD) is a medical device manufacturers whose products are used for early detection of breast, prostate and colorectal cancers. iCAD, Inc. (NASDAQ:ICAD) is using AI in its products. For example, iCAD’s ProFound AI® solution is used in cancer detection systems.

As of the end of the first quarter of 2023, 7 hedge funds in Insider Monkey’s database of 943 funds reported having stakes in iCAD, Inc. (NASDAQ:ICAD). The biggest stakeholder of iCAD, Inc. (NASDAQ:ICAD) during this period was George Mccabe’s Portolan Capital Management which owns a $1.1 million stake in the company

👍️0
tigerpac tigerpac 8 months ago
Hope the company was able raise some money thru “at the market” sale of stock. About to break thru $2 …could it retrace back below $1.50?
👍️0
tigerpac tigerpac 9 months ago
Unfortunately I wouldn’t call a drop from $3.40 to $2.65 in one day “holding up”.

But if you mean from the low six months ago of 1.25 then I see your point. However most of the new names here got in on the July 18 news.

I suspect it will be a several year hold to see how long they stretch out the subscription revenue.
👍️0
skydog526 skydog526 9 months ago
Held up so far.
👍️0
tigerpac tigerpac 9 months ago
Sadly I was correct. Company just issued a $100 million at the market offering (from time to time).

They have about 26 million shares outstanding, 60 million authorized. If fully subscribed they will come close to maxing out A/S or double the current OS shares.

They don’t have to issue any shares if they don’t want to but this filing indicates that they need money and they have to have program in place. Cheaper than borrowing money from a bank right now.
👍️0
tigerpac tigerpac 9 months ago
The subscription model is going to smooth out the revenues however it is also going to extend the length of time that they recognize those revenues.

Based upon the deferred revenue recognition in the last 10-Q it’s likely that the periods of recognition could last 24-36 months.

They have managed to reduce cash burn by 50% but that was before this large order where the customer makes out great since they don’t have to pay everything up front and they too get to pay over time.

I wonder if management is considering an offering at this point in order to capitalize on the news?
👍️0
Gator44 Gator44 9 months ago
ICAD has legs
👍️0
VortMax VortMax 9 months ago
Insurers are going to give mammograms a massive pay raise...preventing missed cases and late stage cases will save insurers billions....and this is just in the USA. Breast cancer is a $30b cost to insurers annually here...a quarter of women in this entire country will be better off now. Over 50m mammograms a year from just RF
👍️0
VortMax VortMax 9 months ago
In just the U.S. this tech can save billions in costlier late stage cancer by finding cancer earlier. Its well worth a few billion bucks to someone if it can save $5b per year...just in America. These mammograms are about to get a massive pay raise from insurers.
👍️0
tigerpac tigerpac 9 months ago
I got out two years ago at 11.50 .

Their revenues and profits shrank and forecasts kept getting missed.

I see they have had some turnover at the top. With the newly signed agreement I just wonder what they had to give up in terms of pricing power in order to land this deal?

Some folks also had advanced knowledge of the deal which was executed on June 27 just about when the stock starting moving from the $1.50 level.
👍️0
VortMax VortMax 9 months ago
its to a point where if you are not using this tech, you won't be able to do a mammogram. the insurers will demand it, one late stage undiagnosed breast cancer can flip a group insurance plan from the black to the red quickly. Can see a company like United buying both RF partners and iCad in a combo deal
👍️0
gapole gapole 9 months ago
Hmmm....might be good for prostate too, don't you think? Same methodology.
👍️0
81vette 81vette 9 months ago
1.6M shares available to short,dropping from 2M is a good sign,fee of 1.79% with 3.29%rebate,paying you to short(looks like a bear trap to me)
👍️0
81vette 81vette 9 months ago
i can only answer that for sure tomorrow,upper bolie is $3.88(1 min) so its not parabolic anymore,we shall see if ppl see this as a buy opportunity,watch for demand and low supply as a tell,promising future company's can attract institutional buying and run it up big in time,(rare find lately) i have had a few this year 700%-300% winners,this looks like a good one to me with future potential,will depend on the black rock crooks to not steal every penny between bid and ask then short into oblivion or will they buy and rocket it up?
👍️0
VortMax VortMax 9 months ago
iCad and the radiologists are going to be able to command much high payments from insurers due to this so that the insurers don't get stuck with undiagnosed or late stage breast cancer at a huge cost to them. Worth billions here, likely can be parlayed into other radiology.....
👍️0
Wkboyd Wkboyd 9 months ago
This still worth buying here?
👍️0
81vette 81vette 9 months ago
the potential is astronomical!,i worked for a guy who invented a lay down on table with holes in it for boobs to go thru and scanner went around boobs,genius idea instead of painfully crushing them against flat surface to scan
👍️0
VortMax VortMax 9 months ago
Product validated, so how much is it worth. Based in NH, healthcare mecca in Boston or NY will buy this for billions to see how it can be used in other radiology.
👍️0
81vette 81vette 9 months ago
only 25M o/s and float excites me.near 1st float rotation now,could start up halts,433K short(not including those who shorted today)nice long is my plan
👍️0
81vette 81vette 9 months ago
potential is huge,1000X revenue with this deal,at least 10Xpps ?,institutions should be getting on soon
👍️0
Monksdream Monksdream 9 months ago
ICAD now No 1 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
81vette 81vette 9 months ago
gaining momentum,getting found
👍️0
gapole gapole 9 months ago
ICAD had nice action today...hod 3.30...
👍️0
AJ Freely AJ Freely 9 months ago
$ICAD - Up 5% Pre-Market/ Current Price $2.06
Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
👍️0
janeyH janeyH 9 months ago
its taking a breather for you to hop in!!
👍️0
Netcool Netcool 9 months ago
Give us time to load ;) $iCAD
👍️0
janeyH janeyH 9 months ago
moving in the right direction ...
👍️0
Monksdream Monksdream 10 months ago
ICAD now No 7 on the Barchart Top 10

https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
janeyH janeyH 10 months ago
Why is this thread not lit up!?!?!

Icad is a huge!!!! Opportunity
👍️0
willlbone willlbone 1 year ago
Looks like a new 10 year low.
Bid 1 dollar
👍️0
Netcool Netcool 1 year ago
$iCAD looking forward to the start of quarter over quarter growth, the relationship with Google and also GE Healthcare just became there own company.
👍️0
dletizia dletizia 1 year ago
Insider buying today
👍️0
dletizia dletizia 1 year ago
On Dec. 5, U.S. stocks were dragged down in part by renewed bearishness on the part of Morgan Stanley (NYSE:MS) analyst Mike Wilson. However, with the U.S. services sector, the job market, and consumer spending holding up quite well, it’s  difficult for me to imagine how the profit collapse predicted by Wilson could materialize. Actually, it’s hard to believe that the earnings of many companies won’t be stronger than expected. Especially if oil prices stay at their current, low levels and overall inflation continues to retreat. Given these points, I think that investors should use the latest decline as an opportunity to buy a number of the best Nasdaq stock picks for 2023 that I will list below.

In addition, I’d take Wilson’s warning with a grain of salt. In June, Wilson suggested that U.S. earnings would plunge. Also worth noting is that, in late June 2022, Wilson suggested that U.S. earnings would plunge, noting, “We see a pretty poor risk reward over the next 3-6 months with recession risk rising in the face of very stubborn inflation readings.” However, U.S. earnings haven’t plunged, and nearly six months later, the S&P 500 has risen 6% above its late June levels, even after yesterday’s slump that was partially induced by Wilson himself. (As of the morning of Dec. 1, the index had jumped nearly 9% above its late June levels). So contrary to popular belief, Wilson’s predictions have been far from perfect this year.

Again, I’d use the latest pullback as an opportunity to pick up some of the best NASDAQ stock picks for 2023.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

TSLA

Tesla

$176.68

PLUG

Plug Power

$13.86

ICAD

iCAD

$1.71

SHLS

Shoals Technologies

$24.47

EXPE

Expedia

$96.24

UAL

United Airlines

$45.42

WDAY

Workday

$160.88

Tesla (TSLA)

?

Tesla (TSLA stock) Motors store in Piazza Gae Aulenti square in Milan, Italy

Source: Zigres / Shutterstock.com

Tesla’s (NASDAQ:TSLA) shares slumped on reports the company would reduce production of its Model Y EV by 20% at its Shanghai plant from Nov.

However, Tesla forcefully denied the report. Even if the news is true, it doesn’t mean that the company’s overall sales growth is slowing. As Barron’s pointed out, Tesla could have decided to reduce production of its Model Y and increase production of one of its other EVs instead. Also possible is that Tesla decided to cut production in China and raise production at another one of its factories simultaneously. In my view, other news involving Tesla and TSLA stock is much more critical. Specifically, the forward price-earnings ratio of TSLA stock, which dropped to just 35.8. That’s very low for a company which is the runaway leader of a booming market.

Finally, Tesla recently made the first deliveries of its full-size truck, the Tesla Semi. Since the EV, according to TSLA, “has triple the power [of] any diesel truck on the road right now.” and can haul a full load 500 miles one one charge, I believe that it will become a major revenue generator for the automaker.

Plug Power (PLUG)

?

Nasdaq in focus accompanied by a green arrow and the word "NYSE"

Source: Shutterstock

Plug Power (NASDAQ:PLUG) continues to make meaningful progress as it seeks to solidify its position as a leader in the green hydrogen revolution. As PLUG opens more of its green hydrogen factories, its margins are poised to meaningfully rise. That’s because the company can produce green hydrogen at its own plants at less cost. Also, the large tax credit for green hydrogen should also be a game changer for PLUG next year. As a result of these upcoming, positive catalysts, the company predicts that its 2023 revenue will come in at $1.4 billion.PLUG also expected to generate “breakeven operating margins” by the end of  next year.

On other fronts, Plug Power’s joint venture with Renault, the giant European automaker, is expected to ramp up next year, as the venture is poised to produce and deliver 800 vans in 2023. Also noteworthy is that Plug Power’s partner, Airbus (OTC:EADSY), the huge European plane manufacturer, recently announced “that it is developing a hydrogen-powered fuel cell engine.” The company intends to begin conducting trials of the engine around 2025 , and the company plans to start building new aircraft that may utilize hydrogen in five to six years.

Consequently, within a year or two, it could become apparent that Airbus is going to buy a large amount of hydrogen from Plug Power. As a result, PLUG stock could very well get a huge boost between the end of 2023, sometime in 2024, or even sooner. As Plug’s potential comes into clearer view next year, PLUG stock should rise dramatically, making the shares one of the best Nasdaq stock picks for 2023.

iCAD (ICAD)

?

Bright signs for Nasdaq (NDAQ) cover the Nasdaq building in Times Square.

Source: Shutterstock

A developer of artificial intelligence-driven products used to detect cancer, iCAD (NASDAQ:ICAD) recently announced  that it had reached a deal with Alphabet’s (NASDAQ:GOOG,NASDAQ:GOOGL) Google Health. Under the agreement, Google Health’s AI will be incorporated “into iCAD’s portfolio of breast imaging AI solutions.”

The deal will constitute the introduction of Google’s breast imaging AI into clinical practice. Moreover, Google agreed to license its AI tevchnology to iCAD. Over the longer term, the deal should be a game changer for iCAD and ICAD stock. First, in the eyes of investors and potential customers, Alphabet’s decision to partner with iCAD should validate iCAD’s technology. Secondly, since Google Health is licensing its technology to iCAD, Alphabet should benefit financially from the proliferation of iCAD’s “breast AI technologies.” As a result, Alphabet is likely to use its huge sales force, gigantic network of contacts, and large amounts of money to boost the sales of iCAD’s tevhnologies.

Trading with a bargain-basement market capitalization of just $43.57 million and just 1.5x sales, iCAD stock does not appear to reflect any of these opportunities.

Shoals Technologies (SHLS)

?

conceptual image of the word NASDAQ surrounded buy red stock chart action

Source: Shutterstock

A developer of components used in solar-energy projects, Shoals (NASDAQ:SHLS) should get a big lift from two recent decisions made by the Biden Administration. Specifically, the administration found that four Chinese solar panel makers did not seek to avoid tariffs by opening factories in nearby Asian countries. Also, in-line with my previous predictions, US Customs and Border Protection released a major proportion of the solar panels hat it had been impounding in response to the Uyghur Forced Labor Prevention Act. The panels were made by China’s JinkoSolar (NYSE:JKS).

Since the U.S. has been suffering from a shortage of solar panels, the moves by the administration should enable more large-scale solar projects to get underway in the country more quickly, reducing Shoals’ “backlog and awarded orders of $471.2 million” and boosting the company’s top and bottom lines. It’s probably not a coincidence that, since both of the Biden administration’s moves were reported on Dec. 2, SHLS stock has climbed nearly 10%. Finally, as I pointed out in a previous column, last quarter, Shoals’ “Revenue was up 52% year over year to $91 million,” and its “Gross margin expanded to 39.7%, up 330 basis points from a year ago, while adjusted earnings of 10 cents per share easily exceeded the 2 cents analysts were calling for.”

Expedia (EXPE)

?

Expedia app logo on a smartphone screen

Source: NYC Russ / Shutterstock.com

Expedia (NASDAQ:EXPE) reported very impressive third-quarter results. From here, the company should continue to benefit from the very strong, pent-up demand for travel well into 2023. Moreover, the valuation of EXPE stock remains very attractive. In Q3, Expedia’s top line climbed 22% year-over-year to a record $3.62 billion, while its operating income, excluding certain items, surged 42% YOY to $747 million. Also, in the first nine months of 2022, Expedia’s free cash flow soared over 100% to $3.1 billion. And the company’s Q3 lodging bookings also set an all-time record last quarter.

Moreover, EXPE CEO Peter Kern reported that the company would resume buying back its stock which the company views as “highly undervalued.” In addition, Wells Fargo (NYSE:WFC) said EXPE’s Q3 results had been “solid,” adding that it is pleased with the company’s loyalty and investment efforts. the firm maintained an “overweight” rating on EXPE.

United Airlines (UAL)

?

a jet takes off on a clear runway.

Source: m.photo / Shutterstock.com

United Airlines (NASDAQ:UAL) was named a top airline pick by Morgan Stanley, which tends to be one of the more bearish firms on the Street. Among the positive catalysts cited by Morgan Stanley analyst Ravi Shanker were a rebound in international travel and the new contract that United signed with its pilots. Shanker added that the airline’s, “Earnings recovery out of the pandemic has kept pace with, if not led, peers,” while widespread concerns about the company’s profitability have been laid to rest. “UAL seems on track to exceed its 2023 guidance and to hit its 2026 guide issued 18 months ago — something even the biggest UAL bulls may have considered difficult at the time.” In addition, analysts at Cowen also said the UAL stock is its top pick among airline stocks, citing the company’s high exposure to international flights.

Workday (WDAY)

?

software stocks: Coding software developer work with augmented reality dashboard computer icons of scrum agile development and code fork and versioning with responsive cybersecurityMore

Source: Shutterstock

Workday (NASDAQ:WDAY) provides software that helps companies manage their human resources and financial applications.

The company reported very strong third-quarter results on Nov. 29. Its revenue jumped 20% year-over-year to $1.6 billion and came in slightly above analysts’ average estimate. More impressively, its operating cash flow increased to $409 million, up from $385 million during the same period a year earlier, while it generated earnings per share of 99 cents, well ahead of analysts’ average estimate of 84 cents. “We are well-positioned in this type of [macro] environment because our cloud finance and HR solutions are truly mission-critical. As our Q3 results showed, more and more organizations are selecting Workday as their trusted partner to help them successfully navigate today’s changing world,” Workday CEO Aneel Bhusri said during the company’s Q3 earnings call.

Further, the company announced a new, $500 million share buyback plan.  In a note to investors, investment firm Monness, Crespi, Hardt wrote that the company has “a large market opportunity” and is carrying out its initiatives well. However, the firm kept a “neutral” rating on the shares, citing macro issues. But, as I indicated in my introduction, I believe that worries about the macro issues are overdone.

On the date of publication, Larry Ramer owned shares of SHLS,JKS,ICAD and PLUG. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.

More From InvestorPlace

Buy This $5 Stock BEFORE This Apple Project Goes Live

The Best $1 Investment You Can Make Today

Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

It doesn’t matter if you have $500 or $5 million. Do this now.

The post Our 7 Top Nasdaq Stock Picks for 2023 appeared first on InvestorPlace.

👍️0

Your Recent History

Delayed Upgrade Clock